a. Typical clearance for a subject with a particular covariate combination = CL/F × θ2 × θ3 × (CrCL/107 mL/min) θ4; where θ2 = 1 for healthy volunteers, θ3 = 1 for males, and θ4 is the exponent for the effect of CrCL on CL/F. b. Typical volume of central compartment for a subject with a particular covariate combination = Vc × θ5 × (BW/74kg) θ6; Where θ5 = 1 for males and θ6 is the exponent for the effect of bodyweight on Vc.
c. Parameter was modeled as exponent of an estimated parameter theta.
d. The fraction (Frac) and the associated ISV were modeled using a reverse logit transformation Frac = exp(θ1 + η)/(exp(θ1+ η)+1).
e. Shrinkage of the newly estimated parameters was as follows: ETA shrinkage on KAIR was 30%, on ALAG1IR 67%, on D2 66%, on KAER 40%, on ALAG1ER 9.3%, on bioavailability of the extended-release formulation relative to the immediaterelease formulation 15%, and on fraction of extended-release dose absorbed through first-order process 50%.
